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Abstract
Consumption of plant flavonoids, antioxidants, and n-3 fatty acids is proposed to have many potential health 
benefits derived primarily through antioxidant and anti-inflammatory activities. This study examined the effects of 
1,000 mg quercetin + 1,000 mg vitamin C (QC); 1,000 mg quercetin, 1,000 mg vitamin C, 400 mg isoquercetin, 
30 mg epigallocatechin gallate, and 400 mg n-3 fatty acids (QFO); or placebo (P), taken each day for 2 wk 
before and during 3 d of cycling at 57% Wmax for 3 hr, on plasma antioxidant capacity (ferric- reducing ability 
of plasma [FRAP], oxygen-radical absorbance capacity [ORAC]), plasma oxidative stress (F2-isoprostanes), and 
plasma quercetin and vitamin C levels. Thirty-nine athletes were recruited and random- ized to QC, QFO, or P. 
Blood was collected at baseline, after 2 wk supplementation, immediately postexercise, and 14 hr postexercise. 
Statistical design used a 3 (groups) × 4 (times) repeated-measures ANOVA with post hoc analyses. Plasma 
quercetin was significantly elevated in QC and QFO compared with P. Plasma F2- isoprostanes, FRAP, and vitamin 
C were significantly elevated and ORAC significantly decreased immediately postexercise, but no difference was 
noted in the overall pattern of change. Post hoc analyses revealed that the QC and QFO groups did not exhibit a 
significant increase in F2-isoprostanes from baseline to immediately postexercise compared with P. This study 
indicates that combining flavonoids and antioxidants with n-3 fatty acids is effective in reducing the immediate 
postexercise increase in F2-isoprostanes. Moreover, this effect occurs independently of changes in plasma 
antioxidant capacity.
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Recently, there has been interest in the potential 
antioxidant and anti-inflammatory activities of plant-
based compounds such as flavonoids (Manach, Hubert, 
Llorach, & Scalbert, 2009; Manach, Williamson, Morand, 
Scalbert, & Remesy, 2005). These compounds may 
have important health benefits and consequences, but 
human studies are limited regarding the compounds and 
even more so when used in conjunction with exercise 
(McAnulty et al., 2008; Nieman, Henson, Davis, et al., 
2007). One of the most often-studied flavonoids is quer-
cetin, which is found in abundance in red wine, onions, 
red grapes, apples, tea, broccoli, and other green leafy 
vegetables. Previous research has reported quercetin 
to display metal-chelating ability and high antioxidant 
capacity (Manach et al., 2009; Manach, Williamson, et 
al., 2005). Humans can absorb large amounts of quercetin, 
which has an estimated plasma half-life ranging from 3.5 
to 28 hr (Manach, Scalbert, Morand, Remesy, & Jimenez, 
2004). In addition, epidemiological studies indicate 
that elevated quercetin consumption is associated with 
reduced risk of heart disease, diabetes, and various types 
of cancer (Manach, Mazur, & Scalbert, 2005; Seeram, 
Adams, Hardy, & Heber, 2004).
Despite these proposed benefits and antioxidant 
actions, two articles (McAnulty et al., 2008; Nieman, 
Henson, Davis, et al., 2007) report that 3 weeks supple-
mentation of 1,000 mg quercetin per day failed to counter 
exercise-induced alterations in immunity, inflammation, 
and oxidative stress. One potential reason for a lack of 
positive outcomes with that study was that the quercetin 
supplements were ingested 10–24 hr before the comple-
tion of exercise. This may have caused too much of a 
delay in peak plasma quercetin metabolites, given the 
short half-life of quercetin (Manach et al., 2004). The 
short half-life suggests that a dose given within an hour 
of exercise may be more beneficial in reducing oxida-
tive stress. Furthermore, it is known that coingestion 
of quercetin with other flavonoids such as catechins 
extends quercetin’s bioavailability and potential bioactive 
effects (Manach & Donovan, 2004; Manach et al., 2004; 
Manach, Williamson, et al., 2005). Catechins such as 
epigallocatechin-3-gallate (EGCG) have been shown in 
animal models to inhibit tumorigenesis during the initia-
tion, promotion, and progression stages and to function 
as chemical antioxidants, which can quench free-radical 
species and chelate transition metals (Lambert & Elias, 
2010). It is not yet known whether ingestion of indi-
vidual flavonoids results in blood concentrations capable 
of exerting systemic antioxidant effects in vivo (Guo, 
Kong, & Meydani, 2009; Hagl et al., 2010; Halliwell, 
2007, 2008). Therefore, coingestion of flavonoids and 
antioxidants might be beneficial in increasing absorption 
and extending bioavailability.
The n-3 fatty acids are of interest as a supplement 
and comprise a family of unsaturated fatty acids that 
mainly consists of α-linoleic acid, eicosapentaenoic 
acid, and docosahexaenoic acid. These fatty acids have 
recently been touted to exert positive effects by reducing 
inflammation (Das, Ramos, & Meguid, 2003). Although 
n-3 fatty acids have been heavily researched for potential
benefit against certain diseases, questions remain about
their abilities to decrease oxidative damage and inflam-
mation when supplemented in conjunction with other
antioxidants in athletes (Das et al., 2003; McAnulty et
al., 2010).
Therefore, given the potential importance of fla-
vonoid compounds, antioxidants, and n-3 fatty acids in 
reducing oxidative stress and inflammation and consider-
ing the limited information regarding ingestion of these 
compounds in human health and exercise, our study 
extended and improved on previous work conducted 
in endurance athletes. F2-isoprostanes were used as an 
indicator of oxidative stress. These compounds possess 
potent biological activity, mediate various aspects of 
oxidative stress, and have been shown to be accurate 
markers of lipid peroxidation (Morrow, 2005; Morrow 
& Roberts, 1996, 1997). This study had two specific 
objectives. The first was to test the influence of a quer-
cetin supplement, with or without EGCG, isoquercetin, 
n-3 fatty acids (eicosapentaenoic and docosahexaenoic
acid), and vitamin C, on F2-isoprostanes and plasma
antioxidant capacity before and after a 3-day period of
intensified exercise. The second objective was to deter-
mine whether F2-isoprostanes and antioxidant capacity




Thirty-nine trained male (n = 32) and female (n = 7) 
cyclists were recruited through local and college cycling 
clubs and tested as experimental subjects. Written 
informed consent was obtained from each subject, and 
the experimental procedures were approved by the insti-
tutional review board of Appalachian State University.
Supplementation
The soft-chew supplements were designed by Querce-
gen Pharma (Newton, MA) and prepared by Nutravail 
Technologies (Chantilly, VA). Each placebo (P) soft-
chew contained brown-rice syrup, evaporated cane 
juice, carnuba wax, natural flavors, gelatin, soy lecithin, 
palm oil, glycerin, xylitol, mono- and diglyceride, corn 
starch, carrageenan, sucralose, and 20 kcal energy, 
with citric acid to substitute for the taste of vitamin C 
and FD&C yellow #5 and FD&C blue #1 to substitute 
for the quercetin color. The cyclists were randomized 
to quercetin plus vitamin C (QC; n = 13), which was 
a chew with 250 mg of quercetin, 250 mg vitamin C, 
10 mg niacin, and 200 μg of folic acid; quercetin plus 
other bioactive substances (QFO; n = 14), which con-
tained the same ingredients as QC with an added 100 
mg isoquercetin, 30 mg EGCG, and 100 mg of total 
omega-3 fatty acids (55 mg eicosapentaenoic acid, 45 
mg of docosahexaenoic acid) each; or placebo (P; n = 
12), which was a chew with citric acid to substitute for 
the taste of vitamin C. Under double-blind procedures, 
subjects ingested four QC, QFO, or P soft-chews per day 
(two in the morning at 7–8 a.m., two in the afternoon 
at 2 p.m.) for 14 days before and during a 3-day period 
of intensified exercise.
Research Design
Within 1 week before the start of supplementation, 
subjects reported to the university human performance 
laboratory for orientation and measurement of cardiore-
spiratory fitness. VO2max was determined using a graded 
maximal protocol (25-W increase every 2 min starting 
at 150 W) with the subjects using their own bicycles on 
CompuTrainer Pro Model 8001 trainers (RacerMate, 
Seattle, WA). VO2 and ventilation were measured using 
the MedGraphics CPX metabolic system (MedGraphics 
Corp., St. Paul, MN). Heart rate was measured using a 
chest heart-rate monitor (Polar Electro Inc., Woodbury, 
NY). Basic demographic and training data were obtained 
through a questionnaire. Body composition was measured 
by hydrostatic weighing.
Subjects agreed to avoid the use of large-dose vita-
min/mineral supplements (above 100% of recommended 
dietary allowances), herbs, and medications known to 
affect immune function during the entire study. During 
orientation, they were instructed to follow a diet moderate 
in carbohydrate (using a food list) the weekend before and 
during the 3-day intensified exercise period. At 12–12:30 
p.m. before each 3-hr cycling bout, subjects ingested a
standardized liquid meal (Boost Plus, Mead Johnson
Nutritionals, Evansville, IN) at an energy level of 63 kJ/
kg (15 kcal/kg). Boost Plus is a nutritionally complete,
high-energy oral supplement with an energy density of 6.4
kJ/ml (1.52 kcal/ml) and 16% of energy as protein, 34%
as fat, and 50% as carbohydrate. In quantities of 1,000 ml,
Boost Plus exceeds daily-value recommendations for all
major vitamins and minerals. No other food and beverage
(other than water) was consumed from this meal until the
end of the cycling bout. Subjects ingested 0.5–1 L water
per hour of cycling. Before and after the first 14 days of
supplementation, they provided blood samples at 8 a.m.
after an overnight fast and avoiding exercise training for 
at least 12 hr and before having ingested supplements. 
Subjects then came to the laboratory for 3 consecutive 
days and cycled from 3 to 6 p.m. at ~57% Wmax. During 
the test sessions, subjects cycled on their own bicycles on 
CompuTrainer Pro Model 8001 trainers with the exercise 
load set at ~57% Wmax. Metabolic measurements were 
taken every 30 min of cycling using the MedGraphics 
CPX metabolic system to verify workload. Blood samples 
were obtained immediately after completion of the third 
3-hr exercise bout (6 p.m.) and then again 14 hr later (8
a.m., overnight fasted, and having avoided supplements
since 2 p.m. the previous day).
Blood Samples
Blood samples were drawn from an antecubital vein with 
subjects in the supine position. Routine complete blood 
counts were performed using a Coulter STKS instru-
ment (Coulter Electronics, Hialeah, FL) and provided 
hemoglobin and hematocrit for determination of plasma 
volume change using the method of Dill and Costill 
(1974). Other blood samples were centrifuged in sodium 
heparin or EDTA tubes, and plasma was aliquotted and 
then stored at –80 °C before analysis. Figure 1 illustrates 
the supplement, exercise, and blood-draw schedule.
Plasma Quercetin Analysis
Total plasma quercetin (quercetin and its primary con-
jugates) was measured after solid-phase extraction via 
reversed-phase high-performance liquid chromatography 
with UV detection as previously described (Nieman, 
Henson, Grosset, et al., 2007). Quercetin conjugates 
were hydrolyzed by incubating 500-μl plasma aliquots 
with 10 μl 10% DL-dithiothreitol solution, 50 μl 0.58 M 
acetic acid, and 50 μl of a mixture of β-glucuronidase/
arylsulfatase and crude extract from Helix pomatia 
(Roche Diagnostics Corp., Indianapolis, IN) for 2 hr at 
37 °C. Chromatographic analysis was performed using 
the Ultimate 3000 HPLC-PDA system (Dionex Corp., 
Sunnyvale, CA) with a Gemini C18 column (Phe-
nomenex, Torrance, CA).
Oxidative and Antioxidant Assays
F2-Isoprostanes.  Plasma F2-isoprostanes were deter-
mined using gas-chromatography mass spectrometry as 
previously described (Morrow & Roberts, 1999). Briefly, 
free F2-isoprostanes were extracted from plasma added 
to a deuterated [2H4] PGF2 internal standard. The mixture 
was then added to a C18 Sep Pak column, followed by 
silica solid-phase extraction. F2-isoprostanes were con-
verted to pentafluorobenzyl esters, subjected to thin-layer 
chromatography, and converted to trimethylsilyl ether de- 
rivatives. Samples were analyzed by negative-ion chemical-
ionization gas-chromatography mass spectrometry using 
an Agilent 6890N gas chromatography interfaced to an 
Agilent 5975B inert MSD mass spectrometer (Agilent 
Technologies, Inc., Santa Clara, CA).
Ferric-Reducing Antioxidant Potential.  Total plasma 
antioxidant potential was determined by a ferric-
reducing ability of plasma (FRAP) assay according 
to the methodology of Benzie and Strain (1996). The 
basis of this assay is that water-soluble reducing agents 
(antioxidants) in the plasma will reduce ferric ions to 
ferrous ions, which then react with an added chromogen. 
Samples and standards were analyzed in duplicate and 
expressed as ascorbate equivalents based on a physiologic 
ascorbate standard curve (0–1,000 μmol). Intra- and 
interassay coefficients of variation were less than 5% 
and 7%, respectively.
Figure 1 — Supplement, exercise, and blood-draw schedule.
Oxygen-Radical Absorbance Capacity.  The oxygen-
radical absorbance capacity (ORAC) assay was a 
modification of the methodologies of Ou, Hampsch-
Woodill, and Prior (2001). Trolox standards were made 
from a frozen Trolox stock solution, and working solution 
was made daily by thawing an aliquot. A serial dilution 
of the 50-µM Trolox solution was made with working 
buffer solution to produce 25-, 12.5-, and 6.25-μM Trolox 
standards. A fluorescein (Aldrich Chemicals) working 
solution was made with phosphate buffer. Before use, 
the solution was incubated in a water bath at 37 °C until 
thoroughly heated.
The 2, 2′- azobis- 2- methyl- propanimidamide, dihy-
drochloride (AAPH) solution was made by dissolving 
AAPH (Wako Chemical) into incubated phosphate buffer 
immediately before the start of the assay. The microplate 
was prepared and loaded in a forward-then-reverse order 
to avoid possible positional errors. The edge wells were 
left empty or blank (phosphate buffer working solution) 
to reduce the impact of “edge effect” on samples and 
standards, particularly from temperature effects on the 
outside wells. Twenty microliters of sample, blank, and 
Trolox standard solutions were pipetted into appropriate 
wells. Then, 200 μl fluoroscein working solution were 
added to each well using an eight-channel micropipet-
tor. A cover was placed on the microplate, and the plate 
and contents were incubated at 37 °C for at least 20 min. 
Then, 20 μl AAPH working solution were added using 
an eight-channel micropipettor as quickly as possible. 
Final ORAC values (μM/L Trolox) were made from 
the plate-reader-derived area under the curve. Then, the 
final ORACFL values were calculated with a quadratic-
regression equation: 
x b b ac cy= − ± − +2 44
Vitamin C.  Vitamin C concentration of duplicate plasma 
samples was determined according to an adaptation of 
the methodology of Blake (2007). Briefly, a standard 
curve was developed using vitamin C standards in 10% 
TCA (Sigma, St. Louis, MO) over a concentration range 
of 0–25 μM. Plasma samples were then centrifuged at 
1,500 g for 15 min at 4 °C, and the supernatant was 
removed and divided into duplicates of 0.5 ml each. 
Then, 0.1 ml of DTC solution was added to each 
standard and sample. The DTC solution consisted of 3.0 
g of dinitrophenylhydrazine (DNPH; Sigma, St. Louis, 
MO), 0.4 g thiourea (Sigma), and 0.05 g copper sulfate 
pentahydrate (Sigma) in a final volume of 100 ml with 
9N sulfuric acid (Fisher Scientific, Pittsburgh, PA).
Samples and standards were gently vortexed, covered 
with aluminum foil, and placed in a water bath at 37 °C 
in a dark room for 3 hr. Each tube was vortexed every 
30 min. Then, 750 μM of 5% sulfuric acid were added 
to each tube and mixed well. The tubes were allowed to 
stand at room temperature in the dark for 1 hr and were 
vortexed gently after 30 min. The absorbance of each 
standard and sample was then read at 515 nm, and the 
blank absorbance was subtracted. Sample concentrations 
were determined by a linear-regression line derived from 
a vitamin C standard curve.
Statistical Analysis
Data are expressed as M ± SD. Data in Table 1 were 
compared between groups using one-way ANOVA. Data 
in Figures 2 through 6 were analyzed using a 3 (groups) 
× 4 (time points) repeated-measures ANOVA with Tukey 
post hoc comparisons. Changes across the four time 
points were calculated and compared within groups. 
Significance for all comparisons was set at p ≤ .05. This 
data analysis allowed group comparisons for three differ-
ent effects: 2 weeks chronic supplementation (pre- and 
postsupplementation), acute postexercise changes, and 
14-hr postexercise recovery.
Results
Subject characteristics for the 39 cyclists randomized 
to QC (11 men, 2 women), QFO (11 men, 3 women), 
and P (10 men, 2 women) and completing all phases of 
the study are summarized in Table 1. Outcome data for 
male and female cyclists did not differ significantly and 
are presented together for each group. No significant 
differences were found between groups for age, body 
composition, training history, or maximal performance 
measures. Plasma volume change did not differ between 
groups postexercise on the third day and averaged less 
than 2% as a result of ingestion of 0.5–1.0 L water per 
hour of exercise (data not shown).
Table 1 Subject Characteristics (N = 39), M ± SD
Variable P (n = 12) QFO (n = 14) QC (n = 13) p
Age (years) 26.3 ± 1.7 28.1 ± 2.8 26.8 ± 2.6 .747
Weight (kg) 72 ± 4 71.8 ± 2.9 72.6 ± 3.8 .920
Body fat (%) 11.4 ± 1.7 12.2 ± 1.7 14.1 ± 1.6 .486
Training (km/week) 308 ± 40 248 ± 27 227 ± 25 .295
Maximal VO2 (ml ∙ kg–1 ∙ min–1) 60.2 ± 1.8 60.3 ± 2.2 61.4 ± 2.3 .796
Maximal power (W) 308 ± 12 321 ± 16 301 ± 17 .553
Maximal heart rate (beats/min) 189 ± 3 184 ± 2 187 ± 2 .352
Note. P = placebo; QFO = quercetin, flavonoids, and omega-3 fatty acids; QC = quercetin and vitamin C; VO2 = volume of oxygen consumption.
Figure 2 — Plasma quercetin concentrations in placebo (n = 12), quercetin (n = 13), and quercetin plus EGCT (n = 14) groups 
presupplement, postsupplement, after 3 days of exercise, and 14 hr recovery, M ± SD. Treatment × Time interaction p = .008. *Sig-
nificantly different from placebo (p ≤ .05). 
Figure 3 — Plasma F2-isoprostane values in placebo (n = 12), quercetin (n = 13), and quercetin plus EGCT (n = 14) groups pre-
supplement, postsupplement, after 3 days of exercise, and 14 hr recovery, M ± SD. Main effects were treatment (p = .497), time (p 
≤ .001), and Treatment × Time interaction (p = .144). *Significantly different from presupplement (p ≤ .01). 
Figure 4 — Plasma ferric-reducing ability of plasma (FRAP) values in placebo (n = 12), quercetin (n = 13), and quercetin plus 
EGCT (n = 14) groups presupplement, postsupplement, after 3 days of exercise, and 14 hr recovery, M ± SD. Main effects were 
treatment (p = .101), time (p ≤ .001), and Treatment × Time interaction (p = .917). 
Figure 5 — Plasma oxygen-radical absorbance capacity (ORAC) values in placebo (n = 12), quercetin (n = 13), and quercetin plus 
EGCT (n = 14) groups presupplement, postsupplement, after 3 days of exercise, and 14 hr recovery, M ± SD. Main effects were 
treatment (p = .104), time (p = .024), and Treatment × Time interaction (p = .351). 
After 2 weeks of consuming two soft-chew supple-
ments at 8 a.m. and 2 p.m. each day, overnight-fasted 
plasma quercetin levels were 36% and 62% above 
presupplementation levels in the QC and QFO groups, 
respectively, compared with a 24% decrease in P (Figure 
2). After the third day of exercise, plasma quercetin levels 
at 6 p.m. (i.e., 4 hr after the last supplement dose) were 
221% and 364% above presupplementation levels in the 
QC and QFO groups, respectively. At 14-hr postexercise, 
a significant 111% increase in plasma quercetin levels 
was measured in the QFO group.
F2-isoprostanes were elevated as a result of exercise 
(time effect p ≤ .001), but no overall treatment effects 
were found. However, after post hoc analysis between 
baseline and immediately postexercise, groups QC 
and QFO did not exhibit a significant increase in F2- 
isoprostanes compared with P. Postexercise increases 
were QFO 15%, QC 26%, and P 62% (Figure 3). FRAP 
was also elevated as a result of exercise (time effect p ≤ 
.001; Figure 4), whereas ORAC values declined postexer-
cise (time effect p = .017; Figure 5). However, no overall 
treatment or post hoc effects or differences were found 
for FRAP or ORAC (Figures 4 and 5, respectively).
Plasma vitamin C values exhibited an increase after 
exercise (time effect, p ≤ .001), but no overall treatment 
effects were found. Exercise caused a 35% increase in P, 
34% increase in QA, and 28% increase in QOF (Figure 
6). In addition, a significant but weak inverse correlation 
(p = .002, r = –.239) was found between F2-isoprostanes 
and vitamin C, but no other significant correlations were 
observed.
Discussion
The main outcome found in this investigation was that 
supplementation with combinations of quercetin, isoquer-
cetin, vitamin C, n-3 fatty acids, and EGCG (catechin) 
prevented significant increases in F2-isoprostanes imme-
diately after 3 days of strenuous cycling versus placebo. 
This occurred despite a demonstrated lack of change in 
antioxidant status. It is not possible from our investiga-
tion to determine precisely which agent or combinations 
were responsible for the F2-isoprostane reduction, but 
this should be systematically investigated in the future. 
Although the complete ramifications are not known con-
cerning exercise, it is known that F2-isoprostanes possess 
potent biological activity and mediate various aspects of 
oxidative stress. A number of studies have shown them 
to be accurate markers of lipid peroxidation and to be 
associated with several human diseases such as obesity, 
diabetes, and atherosclerosis (Morrow, 2005; Morrow & 
Roberts, 1996, 1997). There was no effect of the chronic 
14 days of supplementation on F2-isoprostanes or any 
antioxidant measure. The postexercise suppression of 
F2-isoprostanes in the QA and QFO groups after 3 days 
of exercise must have resulted from the effects of acute 
ingestion. This brings out the possible importance of the 
half-life in the blood of the flavonoids and the importance 
of maximum blood concentrations of flavonoids and n-3 
fatty acids when exercise is conducted.
Because we observed no changes in antioxidant 
status, it is possible that other mechanisms such as inflam-
matory pathways might have been involved in affecting 
Figure 6 — Plasma vitamin C values in placebo (n = 12), quercetin (n = 13), and quercetin plus EGCT (n = 14) groups presupple-
ment, postsupplement, after 3 days of exercise, and 14 hr recovery, M ± SD. Main effects were treatment (p = .149), time (p ≤ .000), 
and Treatment × Time interaction (p = .203).
F2-isoprostane production. Loke et al. (2008) have sug-
gested that depending on the type of conjugation (sulfate 
vs. gluconate) and the hydroxyl group site of the conju-
gation, anti-inflammatory effects of polyphenols may be 
maintained while antioxidant effects are lost. Davi, Falco, 
and Patrono (2004) reported that the adverse effects of 
inflammatory states may be mediated, at least in part, 
through enhanced lipid peroxidation and production of 
F2-isoprostanes. Many other studies have examined vari-
ous disease states and found clear associations between 
elevated F2-isoprostanes and inflammatory states (Cra-
cowski, Bonaz, Bessard, Bessard, Anglade, & Fournet, 
2002; Jialal, Devaraj, & Venugopal, 2002; Zanconato et 
al., 2004). Exercise has also been shown to induce an 
inflammatory and oxidative state (Nieman et al., 2005; 
Nieman, Davis, et al., 2003; Nieman, Dumke, et al., 
2003). The presence of n-3 fatty acids in the QFO group 
may have reduced inflammation by competition with 
arachidonic acid as a precursor in the cyclo-oxygenase 
pathway. This results in modification of lipid-derived 
eicosanoids and a reduction of inflammatory cytokines, 
which most likely occur by effects on transcription fac-
tors that regulate inflammatory gene expression (Calder, 
2009; Calder & Yaqoob, 2009). Because both QA and 
QFO caused suppression of F2-isoprostanes, it appears 
that quercetin and vitamin C are also effective antioxidant 
agents, and the addition of n-3 fatty acids and other mixed 
flavonoids increases the effectiveness of the supplement 
(26% vs. 15% increase in F2-isoprostanes, respectively). 
The origin of F2-isoprostanes detected in plasma remains 
controversial in that a multitude of tissues such as skel-
etal muscle, red blood cells, and plasma can produce 
F2-isoprostanes (Nikolaidis & Jamurtas, 2009).
We also observed that quercetin supplementation 
dramatically increases circulating plasma values of quer-
cetin. However, in contrast to our hypothesis, this plasma 
increase did not affect plasma antioxidant capacity. This 
finding is counter to previous investigations demonstrat-
ing the efficacy of quercetin as an in vitro antioxidant 
(Manach et al., 2004; Manach et al., 1998). There have 
been few human intervention studies with quercetin, but 
Williamson and Manach (2005) reviewed human stud-
ies using doses from 21 mg to 1,000 mg of quercetin, 
all of which exhibited at least some beneficial effects, 
although those investigations did not use F2-isoprostanes 
as an indicator of oxidative stress. However, McAnulty 
et al. (2008) found that 1,000 mg quercetin per day for 
6 weeks did not suppress F2-isoprostanes or increase 
plasma antioxidant capacity. This lends further support 
to the notion that combinations of polyphenols (as found 
in the human diet) or n-3 fatty acid supplements might 
be necessary to exert biological effects.
Given that there were no treatment effects for 
FRAP and ORAC, our data indicate that the potential 
health benefits attributed to quercetin ingestion might 
occur through mechanisms beyond that related to strict 
antioxidant function. Williams, Spencer, and Rice-Evans 
(2004) suggested that flavonoid metabolites do not act 
as conventional hydrogen-donating antioxidants but 
modulate actions of protein- and lipid-kinase-signaling 
pathways, which result ultimately in modulation of 
gene expression. However, Manach et al. (2004; 1998) 
found that the conjugated metabolites of quercetin still 
exerted antioxidant properties, albeit at about 50% of the 
aglycone form. Quercetin exhibits powerful antioxidant 
activity in vitro because of the presence of a 3,4 B-ring 
hydroxyl group configuration. During quercetin metabo-
lism in humans, substitution of the 3,4 B-ring hydroxyl 
groups with methyl or glycosyl groups abolishes a large 
amount of the free-radical-scavenging ability (Manach et 
al., 2004; 1998) and is likely the reason for lack of effect 
on the FRAP and ORAC assays. Galleano, Verstraeten, 
Oteiza, and Fraga (2010) suggest that the actual concen-
trations reached by flavonoids in most animal and human 
tissues after dietary ingestion are incompatible with the 
kinetic requirements necessary to reach reaction rates 
of physiological relevance and that other mechanisms 
are responsible for reducing oxidative stress and inflam-
mation, such as interactions with membrane lipids and 
protein–flavonoid interactions. Our results indicate that 
the antioxidant capacity of quercetin and blood plasma is 
not additive in any form that contributes to preservation 
of reducing compounds able to demonstrate results with 
the FRAP or ORAC assays.
Plasma antioxidant capacity increased significantly 
as a result of exercise in the case of the FRAP assay 
but as previously stated was not affected by any of 
the supplement combinations. This increase in plasma 
antioxidant capacity detected by the FRAP assay most 
likely represents urate and ascorbate released into the 
blood during exercise (McAnulty et al., 2007; Yanai & 
Morimoto, 2004). Conversely, plasma ORAC values 
declined significantly and similarly between treatments 
after exercise, suggesting depletion of one or more 
antioxidants. Briviba et al. (2007) found no significant 
changes in ORAC after bouts of acute ultraendurance 
exercise. In contrast, Neubauer et al. (2010) found ORAC 
to be significantly increased immediately after an Iron-
man triathlon. The uniqueness of the ORAC assay versus 
other antioxidant assays is that total antioxidant capacity 
of a sample is estimated by taking an oxidation reaction 
to completion. ORAC measures all the nonprotein anti-
oxidants, which include alpha-tocopherol, glutathione, 
vitamin C, beta-carotene, uric acid, and bilirubin. In 
this regard, it is more of a comprehensive antioxidant 
measurement encompassing multiple antioxidants (Cao, 
Verdon, Wu, Wang, & Prior, 1995). These results con-
firm that the total antioxidant capacity of blood plasma 
is complex and highly regulated and that using different 
antioxidant assays will result in different outcomes after 
exercise. Because each assay measures a different anti-
oxidant fraction (water and lipid soluble, respectively), 
one should be aware of this when using these assays to 
make assessments in exercise studies. FRAP and ORAC 
results were not correlated, and plasma vitamin C values 
were also not correlated with either antioxidant measure.
In summary, supplementation with combinations of 
quercetin, vitamin C, isoquercetin, EGCG catechin, and 
n-3 fatty acids for 2 weeks reduced F2-isoprostanes imme-
diately postexercise from baseline compared with pla-
cebo. However, despite the reduction in F2-isoprostanes,
the supplementation did not alter plasma antioxidant
capacity, which implies that quercetin and other flavo-
noids exert beneficial health effects from mechanisms
unrelated to antioxidant functions.
Acknowledgments
This study was funded by a research grant from Quercegen 
Pharma, Newton, MA.
References
Benzie, I.F., & Strain, J.J. (1996). The ferric reducing ability 
of plasma (FRAP) as a measure of “antioxidant power”: 
The FRAP assay. Analytical Biochemistry, 239, 70–76.
Blake, C.J. (2007). Analytical procedures for water-soluble 
vitamins in foods and dietary supplements: A review. 
Analytical and Bioanalytical Chemistry, 389, 63–76.
Briviba, K., Stracke, B.A., Rufer, C.E., Watzl, B., Weibel, F.P., 
& Bub, A. (2007). Effect of consumption of organically 
and conventionally produced apples on antioxidant activity 
and DNA damage in humans. Journal of Agricultural and 
Food Chemistry, 55, 7716–7721.
Calder, P.C. (2009).  Polyunsaturated fatty acids and inflam-
matory processes: New twists in an old tale. Biochimie. 
Advance online publication.
Calder, P.C., & Yaqoob, P. (2009). Omega-3 polyunsaturated 
fatty acids and human health outcomes. BioFactors 
(Oxford, England), 35, 266–272.
Cao, G., Verdon, C.P., Wu, A.H., Wang, H., & Prior, R.L. 
(1995). Automated assay of oxygen radical absorbance 
capacity with the COBAS FARA II. Clinical Chemistry, 
41, 1738–1744.
Cracowski, J.L., Bonaz, B., Bessard, G., Bessard, J., Anglade, 
C., & Fournet, J. (2002). Increased urinary F2-isoprostanes 
in patients with Crohn’s disease. The American Journal of 
Gastroenterology, 97, 99–103.
Das, U.N., Ramos, E.J., & Meguid, M.M. (2003). Metabolic 
alterations during inflammation and its modulation by 
central actions of omega-3 fatty acids. Current Opinion 
in Clinical Nutrition and Metabolic Care, 6, 413–419.
Dill, D.B., & Costill, D.L. (1974). Calculation of percentage 
changes in volumes of blood, plasma, and red cells in 
dehydration. Journal of Applied Physiology, 37, 247–248.
Galleano, M., Verstraeten, S.V., Oteiza, P.I., & Fraga, C.G. 
(2010). Antioxidant actions of flavonoids: Thermody-
namic and kinetic analysis. Archives of Biochemistry and 
Biophysics, 501, 23–30.
Guo, W., Kong, E., & Meydani, M. (2009). Dietary polyphe-
nols, inflammation, and cancer. Nutrition and Cancer, 
61, 807–810.
Hagl, S., Deusser, H., Soyalan, B., Janzowski, C., Will, F., 
Dietrich, H., . . . & Richling, E. (2010). Colonic availability 
of polyphenols and D-(-)-quinic acid after apple smoothie 
consumption. Molecular Nutrition and Food Research. 
Advance online publication.
Halliwell, B. (2007). Dietary polyphenols: Good, bad, or 
indifferent for your health? Cardiovascular Research, 
73, 341–347.
Halliwell, B. (2008). Are polyphenols antioxidants or pro-
oxidants? What do we learn from cell culture and in vivo 
studies? Archives of Biochemistry and Biophysics, 476, 
107–112.
Jialal, I., Devaraj, S., & Venugopal, S.K. (2002). Oxidative 
stress, inflammation, and diabetic vasculopathies: The 
role of alpha tocopherol therapy. Free Radical Research, 
36, 1331–1336.
Lambert, J.D., & Elias R.J. (2010).  The antioxidant and pro-
oxidant activities of green tea polyphenols: A role in cancer 
prevention. Archives of Biochemistry and Biophysics, 
501,  65–72.
Loke, W.M., Proudfoot, J.M., Stewart, S., McKinley, A.J., 
Needs, P.W., Kroon, P.A., . . . Kroft, K.D. (2008). Meta-
bolic transformation has a profound effect on anti-inflam-
matory activity of flavonoids such as quercetin: Lack of 
association between antioxidant and lipoxygenase inhibi-
tory activity. Biochemical Pharmacology, 75, 1045–1053.
Manach, C., & Donovan, J.L. (2004). Pharmacokinetics and 
metabolism of dietary flavonoids in humans. Free Radical 
Research, 38, 771–785.
Manach, C., Hubert, J., Llorach, R., & Scalbert, A. (2009). The 
complex links between dietary phytochemicals and human 
health deciphered by metabolomics. Molecular Nutrition 
& Food Research, 53, 1303–1315.
Manach, C., Mazur, A., & Scalbert, A. (2005). Polyphenols and 
prevention of cardiovascular diseases. Current Opinion in 
Lipidology, 16, 77–84.
Manach, C., Morand, C., Crespy, V., Demigne, C., Texier, O., 
Regerat, F., & Remesy, C. (1998). Quercetin is recovered 
in human plasma as conjugated derivatives which retain 
antioxidant properties. FEBS Letters, 426, 331–336.
Manach, C., Scalbert, A., Morand, C., Remesy, C., & Jimenez, 
L. (2004). Polyphenols: Food sources and bioavailability.
The American Journal of Clinical Nutrition, 79, 727–747.
Manach, C., Williamson, G., Morand, C., Scalbert, A., & 
Remesy, C. (2005). Bioavailability and bioefficacy of 
polyphenols in humans. I. Review of 97 bioavailability 
studies. The American Journal of Clinical Nutrition, 81, 
230S–242S.
McAnulty, S.R., Hosick, P.A., McAnulty, L.S., Quindry, J.C., 
Still, L., Hudson, M.B., . . . Austin, M.D. (2007). Effect 
of pharmacological lowering of plasma urate on exercise-
induced oxidative stress. Applied Physiology, Nutrition, 
and Metabolism, 32, 1148–1155.
McAnulty, S.R., McAnulty, L.S., Nieman, D.C., Quindry, 
J.C., Hosick, P.A., Hudson, M.H., . . . DiBarnardi, A.
(2008). Chronic quercetin ingestion and exercise-induced
oxidative damage and inflammation. Applied Physiology,
Nutrition, and Metabolism, 33, 254–262.
McAnulty, S.R., Nieman, D.C., Fox-Rabinovich, M., Duran, V., 
McAnulty, L.S., Henson, D.A., . . . Landram, M.J. (2010). 
Effect of n-3 fatty acids and antioxidants on oxidative 
stress after exercise. Medicine and Science in Sports and 
Exercise, 42, 1704–1711.
Morrow, J.D. (2005). Quantification of isoprostanes as indices 
of oxidant stress and the risk of atherosclerosis in humans. 
Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 
279–286.
Morrow, J.D., & Roberts, L.J. (1996). The isoprostanes. Current 
knowledge and directions for future research. Biochemical 
Pharmacology, 51, 1–9.
Morrow, J.D., & Roberts, L.J. (1997). The isoprostanes: Unique 
bioactive products of lipid peroxidation. Progress in Lipid 
Research, 36, 1–21.
Morrow, J.D., & Roberts, L.J. (1999).  Mass spectrometric 
quantification of F2-isoprostanes in biological fluids and 
tissues as measure of oxidant stress. Methods in Enzymol-
ogy, 300,  3–12.
Neubauer, O., Reichhold, S., Nics, L., Hoelzl, C., Valentini, 
J., Stadlmayr, B., . . . Wagner, K.H. (2010). Antioxidant 
responses to an acute ultra-endurance exercise: Impact 
on DNA stability and indications for an increased need 
for nutritive antioxidants in the early recovery phase. The 
British Journal of Nutrition, 104, 1129–1138.
Nieman, D.C., Davis, J.M., Henson, D.A., Gross, S.J., Dumke, 
C.L., Utter, A.C., . . . Triplett, N.T. (2005). Muscle cytokine
mRNA changes after 2.5 h of cycling: Influence of car-
bohydrate. Medicine and Science in Sports and Exercise, 
37, 1283–1290.
Nieman, D.C., Davis, J.M., Henson, D.A., Walberg-Rankin, J., 
Shute, M., Dumke, C.L., . . . McAnulty, L.S. (2003). Car-
bohydrate ingestion influences skeletal muscle cytokine 
mRNA and plasma cytokine levels after a 3-h run. Journal 
of Applied Physiology (Bethesda, Md.), 94, 1917–1925.
Nieman, D.C., Dumke, C.I., Henson, D.A., McAnulty, S.R., 
McAnulty, L.S., Lind, R.H., & Morrow, J.D. (2003). 
Immune and oxidative changes during and following the 
Western States Endurance Run. International Journal of 
Sports Medicine, 24, 541–547.
Nieman, D.C., Henson, D.A., Davis, J.M., Angela, M.E., Jen-
kins, D.P., Gross, S.J., . . . Mayer, E.P. (2007). Quercetin’s 
influence on exercise-induced changes in plasma cytokines 
and muscle and leukocyte cytokine mRNA. Journal of 
Applied Physiology (Bethesda, Md.), 103, 1728–1735.
Nieman, D.C., Henson, D.A., Gross, S.J., Jenkins, D.P., Davis, 
J.M., Murphy, E.A., . . . Mayer, E.P. (2007). Quercetin
reduces illness but not immune perturbations after inten-
sive exercise. Medicine and Science in Sports and Exercise,
39, 1561–1569.
Nikolaidis, M.G., & Jamurtas, A.Z. (2009). Blood as a reactive 
species generator and redox status regulator during exer-
cise. Archives of Biochemistry and Biophysics, 490, 77–84.
Ou, B., Hampsch-Woodill, M., & Prior, R.L. (2001). Develop-
ment and validation of an improved oxygen radical absor-
bance capacity assay using fluorescein as the fluorescent 
probe. Journal of Agricultural and Food Chemistry, 49, 
4619–4626.
Seeram, N.P., Adams, L.S., Hardy, M.L., & Heber, D. (2004). 
Total cranberry extract versus its phytochemical con-
stituents: Antiproliferative and synergistic effects against 
human tumor cell lines. Journal of Agricultural and Food 
Chemistry, 52, 2512–2517.
Williams, R.J., Spencer, J.P., & Rice-Evans, C. (2004). Flavo-
noids: Antioxidants or signalling molecules? Free Radical 
Biology & Medicine, 36, 838–849.
Williamson, G., & Manach, C. (2005).  Bioavailability and 
bioefficacy of polyphenols in humans. II. review of 93 
intervention studies. American Journal of Clinical Nutri-
tion, 81,  243S–255S.
Yanai, H., & Morimoto, M. (2004). Effect of ascorbate on serum 
lipids and urate metabolism during exhaustive training. 
Clinical Science (London, England), 106, 107–109.
Zanconato, S., Carraro, S., Corradi, M., Alinovi, R., Pasquale, 
M.F., Piacentini, G., . . . Baraldi, E. (2004). Leukotrienes
and 8-isoprostane in exhaled breath condensate of children
with stable and unstable asthma. The Journal of Allergy
and Clinical Immunology, 113, 257–263.
View publication stats
